Australia Markets close in 3 hrs 59 mins

Relay Therapeutics, Inc. (RLAY)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
20.97+0.27 (+1.30%)
At close: 04:00PM EDT
20.97 0.00 (0.00%)
After hours: 04:02PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close20.70
Open20.29
Bid20.12 x 1400
Ask22.92 x 800
Day's range19.63 - 21.40
52-week range12.65 - 38.15
Volume569,005
Avg. volume1,011,564
Market cap2.266B
Beta (5Y monthly)1.44
PE ratio (TTM)N/A
EPS (TTM)-2.84
Earnings date23 Mar 2022 - 28 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est38.88
  • GlobeNewswire

    Relay Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights

    Appointment of Sekar Kathiresan, M.D., CEO of Verve Therapeutics, to board of directors Disclosed three new programs from a growing breast cancer portfolio and a regulatory update on RLY-4008 at June 27th analyst and investor event CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported secon

  • GlobeNewswire

    Relay Therapeutics to Announce Second Quarter 2022 Financial Results and Corporate Highlights

    CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report second quarter 2022 financial results and corporate highlights after the close of market on Thursday, August 4, 2022. The company will not be conducting a teleconference in conjunction with its financial results press release. About Rel

  • GlobeNewswire

    Relay Therapeutics Discloses Anticipated Registrational Path for RLY-4008 in Cholangiocarcinoma and Growing Breast Cancer Franchise at Virtual Analyst and Investor Event

    End-of-phase 1 meeting with the U.S. Food and Drug Administration (FDA) resulted in alignment on the design of a single arm trial for pan-FGFR (FGFRi) treatment-naïve FGFR2-fusion cholangiocarcinoma (CCA) to potentially support accelerated approval Interim data from the once daily (QD) dosing schedule shared with the FDA demonstrated confirmed partial responses in eight out of thirteen (62%) FGFRi-naïve FGFR2-fusion CCA patients, including all four of the patients treated at the registrational t